Latest Asx Listing News

Raptis Group Limited has confirmed the resignation of director James Raptis effective September 30, 2025, amid a sharp rise in its share price and trading volume. The company denies any other undisclosed information behind the recent market activity.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Australian Rare Earths (ASX, AR3) has responded to an ASX price query, denying any undisclosed price-sensitive information and attributing recent trading activity to sector interest and recent company announcements.

Nova Minerals has closed a US$11.1 million underwritten offering on NASDAQ, positioning itself to advance exploration and feasibility studies at its Estelle Gold and Critical Minerals Project in Alaska.

Visionflex Group delivered a standout Q4 FY25, posting $2.1 million in cash receipts and securing transformative contracts that underpin its expanding virtual healthcare footprint.

Pacific Edge Limited (ASX – PEB) has announced a securities purchase plan (SPP) aiming to raise up to NZD 5 million, contingent on shareholder approval of a prior NZD 16 million placement. The move is designed to bolster working capital amid ongoing growth initiatives.

betr Entertainment has unveiled an all-scrip takeover bid for PointsBet, offering shareholders 3.81 betr shares per PointsBet share, valuing the offer above a competing cash bid and promising significant cost synergies.

The ASX has published its latest list of entities suspended from trading for over three months, outlining key deadlines for report lodgement and trading resumption plans. Failure to meet these deadlines risks removal from the official list.

Canyon Resources has begun construction of the Inland Rail Facility and upgraded haulage road in Cameroon, key steps toward first bauxite production and shipment in 2026.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Future Generation Global has reported a strong 20.8% investment portfolio return for the year ending June 2025, prompting an increase in its fully franked interim dividend to 4.0 cents per share. This marks the sixth consecutive year of dividend growth for the ASX-listed investment company.

DigitalX Limited reports a $75.6 million treasury valuation driven by Bitcoin and digital assets, completing a $20.7 million capital raise to expand its Bitcoin-first strategy.